Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway

BACKGROUND: Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide, which is partially due to limited progress of therapy. Apatinib, an inhibitor of VEGFR2, has a promising antitumor effect on malignancies. However, the underlying mechanism of its antitumor effect on esop...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Bin, Wang, Yuanyuan, Wang, Jiawei, Cai, Xiaomin, Xu, Lingyan, Wu, Jingjing, Wang, Ying, Liu, Wen, Gu, Yanhong, Guo, Wenjie, Xu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254695/
https://www.ncbi.nlm.nih.gov/pubmed/32514243
http://dx.doi.org/10.1186/s12935-020-01290-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254695/
https://www.ncbi.nlm.nih.gov/pubmed/32514243
http://dx.doi.org/10.1186/s12935-020-01290-z

Ejemplares similares